Skip to main navigation Skip to search Skip to main content

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

  • Sushrut Kamerkar
  • , Valerie S. Lebleu
  • , Hikaru Sugimoto
  • , Sujuan Yang
  • , Carolina F. Ruivo
  • , Sonia A. Melo
  • , J. Jack Lee
  • , Raghu Kalluri

Research output: Contribution to journal › Article › peer-review

Abstract

The mutant form of the GTPase KRAS is a key driver of pancreatic cancer but remains a challenging therapeutic target. Exosomes are extracellular vesicles generated by all cells, and are naturally present in the blood. Here we show that enhanced retention of exosomes, compared to liposomes, in the circulation of mice is likely due to CD47-mediated protection of exosomes from phagocytosis by monocytes and macrophages. Exosomes derived from normal fibroblast-like mesenchymal cells were engineered to carry short interfering RNA or short hairpin RNA specific to oncogenic Kras G12D, a common mutation in pancreatic cancer. Compared to liposomes, the engineered exosomes (known as iExosomes) target oncogenic KRAS with an enhanced efficacy that is dependent on CD47, and is facilitated by macropinocytosis. Treatment with iExosomes suppressed cancer in multiple mouse models of pancreatic cancer and significantly increased overall survival. Our results demonstrate an approach for direct and specific targeting of oncogenic KRAS in tumours using iExosomes.

Original languageEnglish (US)
Pages (from-to)498-503
Number of pages6
JournalNature
Volume546
Issue number7659
DOIs
StatePublished - Jun 22 2017
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer'. Together they form a unique fingerprint.

Cite this